TITLE:
Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

CONDITION:
Hemophilia B

INTERVENTION:
rFIX

SUMMARY:

      The primary objective of this clinical research study is to establish the bioequivalence of
      2 treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Moderate to severe hemophilia B (FIX: C 2%)

          -  Previously treated patients (PTPs) with 150 documented exposure days

          -  Age  12 years (US sites only)

        Exclusion Criteria:

          -  Detectable factor IX inhibitor defined as 0.6 Bethesda Units for pooled plasma
             reported by the local laboratory (family history of inhibitors will not exclude the
             patient)

          -  Patient history of factor IX inhibitor replacement therapy

          -  Patient unable to be off factor IX replacement therapy for at least 5 days without
             bleeding
      
